Skip to main content
SpringerLink
Log in

Trastuzumab Deruxtecan beim vortherapierten fortgeschrittenen HER2-positiven Magenkarzinom

Trastuzumab deruxtecan in previously treated advanced HER2-positive gastric cancer

  • Journal Club
  • Published:
Der Onkologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Literatur

  1. Bang Y‑J, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687–697. https://doi.org/10.1016/S0140-6736(10)61121-X

    Article  CAS  PubMed  Google Scholar 

  2. Shitara K, Iwata H, Takahashi S et al (2019) Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study. Lancet Oncol 20(6):827–836. https://doi.org/10.1016/S1470-2045(19)30088-9

    Article  CAS  PubMed  Google Scholar 

  3. Thuss-Patience PC, Shah MA, Ohtsu A et al (2017) Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study. Lancet Oncol 18(5):640–653. https://doi.org/10.1016/S1470-2045(17)30111-0

    Article  CAS  PubMed  Google Scholar 

  4. Tabernero J, Hoff PM, Shen L et al (2018) Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol 19(10):1372–1384. https://doi.org/10.1016/S1470-2045(18)30481-9

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Allgemein‑, Viszeral‑, Tumor- und Transplantationschirurgie, Universitätsklinikum Köln (AöR), Kerpener Str. 62, 50937, Köln, Deutschland

    Aylin Pamuk,  Hakan Alakus &  Christiane Bruns

  2. Klinik für Gastroenterologie und Hepatologie, Universitätsklinikum Köln, Köln, Deutschland

    Fabian Kütting

Authors
  1. Aylin Pamuk
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fabian Kütting
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hakan Alakus
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christiane Bruns
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hakan Alakus.

Ethics declarations

Interessenkonflikt

A. Pamuk, F. Kütting, H. Alakus und C. Bruns geben an, dass kein Interessenkonflikt besteht.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pamuk, A., Kütting, F., Alakus, H. et al. Trastuzumab Deruxtecan beim vortherapierten fortgeschrittenen HER2-positiven Magenkarzinom. Onkologe 27, 74–76 (2021). https://doi.org/10.1007/s00761-020-00851-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-020-00851-1

Search

Navigation